PWM
VTVT icon

Perigon Wealth Management’s vTv Therapeutics VTVT Stock Holding History

Perigon Wealth Management’s Portfolio VTVT Stock Details VTVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-2
Closed – – 588
2018
Q1 		$0 Hold
2
– – ﹤0.01% 689
2017
Q4 		$0 Hold
2
– – ﹤0.01% 677
2017
Q3 		$0 Buy
+2
New +$399 ﹤0.01% 719

Other funds holding VTVT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
PP
Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return

Perigon Wealth Management's VTVT Position: Q2 2018 in Review

Perigon Wealth Management sold out of vTv Therapeutics (VTVT) in Q2 2018, closing a stake of 2 shares.

Perigon Wealth Management first reported a position in VTVT in Q3 2017 and held it in 3 quarters. The position peaked at $0 in Q1 2018. 27 funds tracked by Wall St. Rank hold VTVT as of Q2 2018.

  • Perigon Wealth Management reported no remaining vTv Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Perigon Wealth Management sold 2 vTv Therapeutics shares in Q2 2018.
  • Perigon Wealth Management first reported a position in vTv Therapeutics in Q3 2017 and held it in 3 quarters.
  • Perigon Wealth Management's vTv Therapeutics position peaked at $0 in Q1 2018.
  • 27 funds tracked by Wall St. Rank held vTv Therapeutics as of Q2 2018.

Based on Perigon Wealth Management's 13F filing for Q2 2018, filed 7 Aug 2018.